YOUNGBLOOD DR KNEELAND 4
4 · Light & Wonder, Inc. · Filed Jun 12, 2026
Research Summary
AI-generated summary of this filing
Light & Wonder Director Dr. Kneeland Youngblood Converts RSUs, Receives Award
What Happened
Dr. Kneeland Youngblood, a director of Light & Wonder, had 2,391 restricted stock units (RSUs) convert/vest on June 10, 2026 (reported as derivative exercise/conversion) and those 2,391 derivative shares were recorded as disposed on the same date. On the same day she was also granted/awarded 2,498 restricted stock units. The Form 4 shows $0.00 per-share for the conversion/disposition and the award (conversion entries commonly show $0 on these reports); no dollar sale proceeds are reported in the provided filing details.
Key Details
- Transaction date(s): June 10, 2026; Form 4 filed June 12, 2026 (timely filing).
- Transactions reported: conversion/vesting of 2,391 RSUs (code M: exercise/conversion) and simultaneous disposition of those 2,391 derivative shares (code M); grant/award of 2,498 RSUs (code A).
- Reported price/value: $0.00 per share on the Form 4 entries (typical for RSU conversions on these forms); no cash amount for proceeds shown in the provided data.
- Shares owned after the transactions: not specified in the details you provided.
- Footnotes of note:
- F1: Shares are held via CHESS Depositary Interests (CDIs) on the ASX; each CDI equals one share of common stock.
- F2: The 2,391 conversion reflects vesting of RSUs granted June 10, 2025; each unit converted one-for-one into common stock.
- F3: The 2,498 RSUs awarded are scheduled to vest on the earlier of the issuer's 2027 annual meeting or June 10, 2027; each unit converts one-for-one into common stock.
Context
- The filing shows RSU vesting/conversion and an immediate disposition of those converted units; this pattern is common for RSU settlements (e.g., to cover tax withholding or to monetize shares), but the form itself does not state a reason.
- The 2,498-unit award is a time-based RSU grant that has not yet vested and will convert to shares if/when the vesting condition is met.
- These entries relate to equity awards and conversions rather than open-market purchases or sales by the insider for investment signaling purposes; interpret acquisitions (awards) and dispositions (sales) differently when assessing insider activity.
Insider Transaction Report
Form 4
Light & Wonder, Inc.ASX:LNW
YOUNGBLOOD DR KNEELAND
Director
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-06-10+2,391→ 30,555 total - Exercise/Conversion
Restricted Stock Units
[F2]2026-06-10−2,391→ 0 total→ Common Stock (2,391 underlying) - Award
Restricted Stock Units
[F3]2026-06-10+2,498→ 2,498 total→ Common Stock (2,498 underlying)
Footnotes (3)
- [F1]Shares are held via CHESS Depositary Interests ("CDIs"), which are units of beneficial ownership in shares of common stock of the Company that are publicly traded on the Australian Securities Exchange (the "ASX") and held by CHESS Depositary Nominees Pty. Limited, a subsidiary of ASX Limited, the company that operates the ASX. Each CDI represents one fully paid share of common stock.
- [F2]Represents the vesting of restricted stock units granted on June 10, 2025. The award has fully vested. Each restricted stock unit converted into a share of common stock on a one-for-one basis.
- [F3]The restricted stock units are scheduled to vest on the earlier of (a) the date of the issuer's 2027 annual meeting of stockholders and (b) June 10, 2027. Each unit converts into a share of common stock on a one-for-one basis.
Signature
/s/ Sweta Gabhawala, attorney-in-fact for Dr. Kneeland Youngblood|2026-06-12